Heart Failure Treatment Guided by Daxor BVA-100 Lowers Hospital Stay 55%

  Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay (LOS) for heart failure (HF) patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.

https://www.biospace.com/article/releases/new-data-shows-heart-failure-treatment-guided-by-daxor-s-bva-100-lowers-hospital-length-of-stay-by-55-percent-/